Tag:
Genentech
Latest Headlines
Latest Headlines
NIH taps Genentech drug for pioneering Alzheimer's study
Researchers will test crenezumab in Colombians with a particular genetic mutation, aiming to see if the drug can stop Alzheimer's before it starts.
Genentech drug picked for pioneering $100M Alzheimer's trial
Investigators will test the drug in a region of Colombia where a particular genetic mutation is known to trigger the early onset of Alzheimer's.
Roche moves forward with injectable Actemra
Roche's Genentech unit announced that Actemra, the rheumatoid arthritis treatment, delivered "clinically meaningful and comparable results" when administered under the skin.
Biopharma giants call on FDA to demand tough standards for biosimilars
Some of their greatest concerns reflected some clear anxieties about the eventual arrival of cheaper competition.
Virtual is beautiful in biotech
I had the chance to moderate a panel at the BIO-Europe Spring meeting yesterday on new business models in biotech, with Torbjorn Bjerke, David Collier, Kevin Johnson, and Thomas Zioncheck joining the conversation.
Pfizer CEO: More than 50 fakes of our drugs discovered last year
While publicity has focused on the counterfeit Avastin recently discovered in the U.S., the problem of fakes is much more widespread than the pubic realizes. Pfizer CEO Ian Read said the company confirmed more than 50 fakes of its drugs in at least 101 countries just last year.
U.S. market size, shortages lead to more counterfeits
The size of the pharmaceutical market, the number of drugs in short supply, and the fact that many drugs sold in the U.S. are manufactured abroad all fit into the precise formulation for the...
FDA, Roche probe bogus Avastin found in U.S.
Fake Avastin has turned up in the U.S. drug supply. Roche ( $RHHBY ) and its U.S. unit Genentech say they're testing the "drug" in bogus vials, while the FDA and regulators overseas do...
FDA rewards Roche with priority review for blockbuster cancer drug
After racking up a solid set of late-stage data on the experimental breast cancer drug pertuzumab late last year, Roche ( $RHHBY ) and Genentech scored priority review status for the program, shaving
Roche, Pfizer win FDA nods for targeted cancer drugs
Roche ( $RHHBY ) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not
